Improving Patient Adherence and Quality of Life in Challenging Patients with Type 2 Diabetes: Anticipating and Managing Adverse Events Associated with Basal Insulin and GLP-1 Receptor Agonists

A continuing medical education activity provided by NAMCP and AAMCN.

Treatment Advances for Challenging Patients with Type 2 Diabetes: What Managed Care Needs to Know About Fixed-Ration Combinations of Basal Insulin and GLP-1 is a three-part webinar series

This is Part 3 of the series focusing on improving patient adherence and
quality of life in challenging patients with type 2 diabetes

This activity is an archive from the webinar held May 28, 2020

This activity is valid from June 1, 2020 to June 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi US

Description:
The ADA estimates that more than 30.3 million people in the US have diabetes. About 90-95% of adults who have diabetes have type 2 diabetes. According to the CDC, uncontrolled type 2 diabetes (T2DM) doubles a person's risk for death, and on average individuals with T2DM lose 10-15 years of life. The management of T2DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in T2DM management have given HCPs the ability to shrink this clinical practice gap. Fixed-ratio combinations of basal insulin and GLP-1 agonists have shown to improve both clinical and economic outcomes in T2DM patients, especially in challenging cases.

Upon completion of this activity, participants will be able to:

  • Explore challenges to patient adherence and quality of life in challenging patients in type 2 diabetes

  • Review recent clinical data around the safety of fixed-ratio GLP-1RA/basal insulin combination therapies and their effect on patient quality of life

  • Analyze strategies to monitor and manage adverse events associated with fixed-ratio GLP-1RA/basal insulin combination therapies in type 2 diabetes management in order to improve patient adherence

  • Discuss strategies to overcome barriers to the introduction and intensification of fixed-ratio therapies

     

Faculty: Carol H. Wysham, MD
Clinical Professor of Medicine
University of Washington School of Medicine
Clinical Endocrinologist
MultiCare Rockwood Clinic in Spokane

Disclosure:

Dr. Wysham has served as a consultant for Abbott, AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and Sanofi. She serves on the speaker’s bureau for AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and Sanofi. She has received grants or research support from Abbott, Allergan, Gilead, Mylan, and Novo Nordisk. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi US

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue